Growth Metrics

CorMedix (CRMD) Net Income towards Common Stockholders (2016 - 2025)

CorMedix has reported Net Income towards Common Stockholders over the past 16 years, most recently at $14.0 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at $14.0 million for Q4 2025, down 56.9% from a year ago — trailing twelve months through Dec 2025 was $165.1 million (up 14429.32% YoY), and the annual figure for FY2025 was $163.1 million, up 14253.43%.
  • Net Income towards Common Stockholders reached $14.0 million in Q4 2025 per CRMD's latest filing, down from $108.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $108.5 million in Q3 2025 and bottomed at -$14.5 million in Q1 2024.
  • Median Net Income towards Common Stockholders over the past 5 years was $911594.0 (2021), compared with a mean of $6.5 million.
  • The largest annual shift saw Net Income towards Common Stockholders plummeted 250.96% in 2023 before it surged 4008.55% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$9.7 million in 2021, then increased by 15.08% to -$8.2 million in 2022, then tumbled by 74.94% to -$14.4 million in 2023, then surged by 326.52% to $32.5 million in 2024, then plummeted by 56.9% to $14.0 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CRMD at $14.0 million in Q4 2025, $108.5 million in Q3 2025, and $21.9 million in Q2 2025.